Literature DB >> 16510209

Detection of occult tumor cells in lymph nodes from non-small cell lung cancer patients using reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA with the evaluation of its sensitivity.

Jun Maeda1, Masayoshi Inoue, Meinoshin Okumura, Mitsunori Ohta, Masato Minami, Hiroyuki Shiono, Yasushi Shintani, Hikaru Matsuda, Nariaki Matsuura.   

Abstract

We evaluated the usefulness of a real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) method for detecting occult tumor cells in histologically malignant-negative lymph nodes resected from patients with non-small cell lung cancer. First, we examined the relationship between tumor cell number and carcinoembryonic antigen (CEA) mRNA copy number using a PCR method with a cancer cell line (A549) in a serial dilution study. Next, we evaluated the relationship between nodal metastatic area size and CEA mRNA copy number using lymph nodes with histologically proven metastasis in a serial slice study. On the basis of those results, we performed RT-PCR analyses with 28 primary tumors and 211 lymph nodes from 28 patients who underwent a lobectomy with systematic node dissection. Our results in the serial dilution study showed that the detectable limitation by quantitative RT-PCR was 25-100 neoplastic cells and 20-100 CEA mRNA copy numbers. In the serial slice study, we found a correlation between CEA mRNA copy number and nodal metastatic area. In the clinical samples, amplification of CEA mRNA was obtained with all 28 primary tumors and 13 of the lymph nodes with metastasis shown by hematoxylin-eosin staining. Furthermore, 52 (25%) of 211 histologically negative lymph nodes and the specimens from 14 (64%) of the 22 pN0 patients revealed a significant level of CEA mRNA. These results indicate that micrometastases, which are not detectable with conventional examinations, can be detected by the present method of RT-PCR for CEA mRNA in a proportion of patients with resected pN0 non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510209     DOI: 10.1016/j.lungcan.2005.12.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Lymph node micrometastases detected by carcinoembryonic antigen mRNA affect long-term survival and disease-free interval in early-stage lung cancer patients.

Authors:  Mario Nosotti; Alessandro Palleschi; Lorenzo Rosso; Davide Tosi; Luigi Santambrogio; Paolo Mendogni; Antonella Marzorati; Ilaria Righi; Silvano Bosari
Journal:  Oncol Lett       Date:  2012-08-24       Impact factor: 2.967

Review 2.  Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer.

Authors:  Krista J Hachey; Yolonda L Colson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

3.  Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.

Authors:  Valerie W Rusch; Debra Hawes; Paul A Decker; Sue Ellen Martin; Andrea Abati; Rodney J Landreneau; G Alexander Patterson; Richard I Inculet; David R Jones; Richard A Malthaner; Robbin G Cohen; Karla Ballman; Joe B Putnam; Richard J Cote
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

4.  Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method.

Authors:  Noriyoshi Sawabata; Meinoshin Okumura; Tomoki Utsumi; Masayoshi Inoue; Hiroyuki Shiono; Masahito Minami; Toshirou Nishida; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-05

5.  Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Kjetil Boye; Øystein Fodstad; Siri Juell; Lars H Jørgensen; Steinar Solberg; Åslaug Helland; Odd Terje Brustugun; Gunhild Mari Mælandsmo
Journal:  Diagn Pathol       Date:  2016-06-17       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.